Background/Aims: Increasing evidence links microRNAs to the pathogenesis of peripheral vascular disease. We recently found microRNA-125b (miR-125b) to be one of the most significantly down-regulated microRNAs in human arteries with arteriosclerosis obliterans (ASO) of the lower extremities. However, its function in the process of ASO remains unclear. This study aimed to investigate the expression, regulatory mechanisms, and functions of miR125b in the process of ASO. Methods: Using the tissue explants adherent method, vascular smooth muscle cells (VSMCs) were prepared for this study. A rat carotid artery balloon injury model was constructed to simulate the development of vascular neointima, and a lentiviral transduction system was used to overexpress serum response factor (SRF) or miR-125b. Quantitative real-time PCR (qRT-PCR) was used to detect the expression levels of miR-125b and SRF mRNA. Western blotting was performed to determine the expression levels of SRF and Ki67. In situ hybridization analysis was used to analyze the location and expression levels of miR-125b. CCK-8 and EdU assays were used to assess cell proliferation, and transwell and wound closure assays were performed to measure cell migration. Flow cytometry was used to evaluate cell apoptosis, and a dual-luciferase reporter assay was conducted to examine the effects of miR-125b on SRF. Immunohistochemistry and immunofluorescence analyses were performed to analyze the location and expression levels of SRF and Ki67. Results: miR125b expression was decreased in ASO arteries and platelet-derived growth factor (PDGF)-BB-stimulated VSMCs. miR-125b suppressed VSMC proliferation and migration but promoted VSMC apoptosis. SRF was determined to be a direct target of miR-125b. Exogenous miR-125b expression modulated SRF expression and inhibited vascular neointimal formation in ballooninjured rat carotid arteries. Conclusions: These findings demonstrate a specific role of the miR-125b/SRF pathway in regulating VSMC function and suggest that modulating miR-125b levels might be a novel approach for treating ASO.
MicroRNA-125b Affects Vascular Smooth Muscle Cell Function by Targeting Serum Response Factor
Zhibo Chen 
Introduction
Arteriosclerosis obliterans (ASO) of the lower limbs is a common disease, inflicting a 17% morbidity rate in people aged 55 to 75 years, resulting in lower limb ischemia and even amputation. Previous research indicated that nearly 20% of people greater than 65 years of age suffer from limb arterial diseases, and ASO currently ranks as the highest incidence rate [1] . ASO leads to limb physical disabilities in thousands of elderly patients each year and is a serious threat to their health. Furthermore, with changing lifestyles, ASO increasingly occurs among younger age groups, and these trends bring heavy burdens to the families of patients and to the government. Because the effects of current drug treatments are not satisfactory [2] , vascular interventional therapies, such as balloon angioplasty and stent angioplasty, have become the main therapeutic option [3] . Although interventional therapy brings immediate relief, the recurrence rate of narrowing reaches 30%-50% within 1 year, and nearly 12% of severe lower limb ischemia necrosis cases result in amputation [4] , bringing enormous sadness to the patients and their families.
Vascular smooth muscle cells (VSMCs) are the main cells comprising the medial artery layer, which is involved in most vascular diseases. VSMC phenotypic changes, resulting in excessive proliferation and migration, are well known to be the main factors leading to ASO onset and the main cause of restenosis after interventional therapy [5] . However, how VSMCs affect the ASO process via phenotypic changes and their internal control mechanism has not been fully elucidated.
MicroRNAs are a family of highly conserved, small noncoding RNAs that can exert posttranscriptional repression functions in target gene proteins through the direct degradation or inhibition of target mRNAs involved in diverse cell functions [6] [7] [8] . Regarding arterial occlusive diseases, microRNAs regulate the functions of arterial smooth muscle cells, endothelial cells and macrophages, consequently affecting the onset and progression of ASO [9] [10] [11] . Previous studies have verified that the microRNAs miR-21, miR-143 and miR-221 are involved in the onset of occlusive vascular disease [12] [13] [14] .
To study relationships between microRNAs and ASO, we collected normal femoral arteries and ASO arteries for microRNA chip screening, revealing that the expression levels of microRNAs associated with ASO were abnormal. Among these microRNAs, the aberrant expression of miR-21 and miR-1298 was verified by RT-qPCR. Using the chip screening result as a cue, miR-21 was verified to be up-regulated by HIF-1. In addition, miR-21 has been shown to regulate the proliferation and migration of VSMCs, consequently impacting the onset and progression of ASO via targeting TPM1 [12] . Furthermore, miR-1298 deficiency was related to its DNA upstream of the CpG hypermethylation site in ASO, and miR-1298 down-regulation was shown to serve a modulatory role in vascular neointimal growth and function by regulating the proliferation and migration of VSMCs via directly targeting Connexin 43 [15] .
In follow-up e xperiments in animals, microRNAs were differentially expressed in various stages of atherosclerosis (e.g., the down-regulation of miR-125b) [16] . The abnormally expressed microRNAs identified in this study are closely associated with the pathogenesis of atherosclerosis. Based on its aberrant expression at various stages of atherosclerosis, miR-133a has been recognized to regulate the functions of artery smooth muscle cells by targeting RhoA and is involved in the pathogenesis of arterial sclerosis occlusion, a kind of atherosclerosis of the lower extremities [17] .
We also found miR-125b to be down-regulated in ASO arterial specimens and experimental ApoE -/-mice during a previous microRNA chip screening experiment. Furthermore, miR-125b is also down-regulated in many kinds of tumor cells, including hepatocellular carcinoma [18] , breast carcinoma [19] , oophoroma [20] , urinary bladder carcinoma [21] and leucocythemia [22] . When miR-125b expression is up-regulated, the proliferation and invasive abilities of these cancer cells are suppressed, inducing cellular apoptosis. The disease characteristics of ASO are similar to those of tumors, and they share some common molecular mechanisms, such as aberrant cell proliferation and migration [23] . )  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23 F  F  F   66  65  73  60  56  64  58  68  71  55  62  67  63  58  56  66  36  42  40  51  32  45  39  54   ASO  ASO  ASO  ASO  ASO  ASO  ASO  ASO  ASO  ASO  ASO  ASO  ASO  ASO  ASO  ASO  Normal  Normal  Normal  Normal  Normal  Normal  Normal  Normal   30  -50  ---30  40  50  30  20  -40  35  ----------40  40  40  -20  -30  40  50  30  20  40  40  40  30  30  --------10  15  20  8  -15  -10  15  -10  10  5  10  -15  ------- Evidence indicates that the down-regulation of miR-125b is a potential factor underlying the excessive proliferation and migration of VSMCs in ASO.
Because the function of miR-125b in ASO has not been reported, we sought to clarify the functions and molecular mechanisms of miR-125b in ASO using a series of arterial specimens, in vitro VSMCs, and animal experiments. We expect these studies to provide novel means for the diagnosis or future clinical therapeutic applications of ASO.
In this study, miR-125b was expressed mainly in arterial specimen medium, as its expression was low in neointimal ASO formation and VSMCs stimulated with platelet-derived growth factor-BB (PDGF-BB) cultured in vitro. Up-regulation of miR-125b suppressed the proliferation and migration of proliferative VSMCs and promoted cell apoptosis, and miR125b lentivirus suppressed neointimal formation in a rat carotid artery balloon injury model via targeting serum response factor (SRF).
Materials and Methods
Sample acquisition and cell culture ASO artery samples were obtained from 16 patients with severe ASO who underwent lower limb amputation, and normal lower limb artery samples were acquired from 8 donors without ASO. Consent was obtained from either the donors or their family members. This study was approved by the Research Ethics Committee of the First Affiliated Hospital of Sun Yat-sen University (Authorization No.201502) and conformed to the Declaration of Helsinki. All samples were snap-frozen in liquid nitrogen immediately following the arteriotomy until RNA was extracted. Some of the samples were fixed with 4% paraformaldehyde and embedded in wax for further analyses. Detailed information regarding the patients and donors is provided in Table 1 .
Primary human VSMCs were obtained from normal lower limb arteries using the tissue explants adherent method. VSMCs were cultured in Dulbecco's Modified Eagle's Medium (DMEM) (Invitrogen, Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% fetal bovine serum (FBS, Invitrogen) and 100 μg/ml penicillin/streptomycin (Invitrogen) at 37°C in a humidified incubator at 5% CO 2 .
RNA interference miR-125b mimics (60 nmol/L) (RiboBio, Co., Ltd. Guangzhou, China) were used for imitation, and a miR-125b inhibitor (60 nmol/L) (RiboBio) was used to deplete endogenous miR-125b. VSMCs were seeded into culture wells 24 h before transfection and transfected with the Lipofectamine ® RNAiMAX (Invitrogen) transfection reagent according to the manufacturer's instructions. Transfection complexes were prepared and mixed either with the miR-125b mimics or the miR125b inhibitor in parallel with their respective control oligos (RiboBio, 60 nmol/L). The transfection medium was replaced with regular cell culture medium 12 h after transfection. Sequences of the miR-125b mimics and the miR125b inhibitor are shown in Table 2 . For miR-125b amplification, the PCR conditions were as follows: 95°C for 10 sec; 39 cycles of 95°C for 5 sec and 60°C for 20 sec, followed by a third step at 95°C for 15 sec and 65°C for 10 sec; and a final hold at 95°C. For SRF mRNA amplification, the PCR conditions were as follows: 95°C for 30 sec; 39 cycles of 95°C for 3 sec and 60°C for 30 sec, followed by a third step at 95°C for 15 sec and 60 °C for 10 sec; and a final hold at 95°C. Relative SRF and miR-125b expression levels were calculated according to the comparative cycling threshold (CT) method using the expression of the housekeeping genes U6 small nuclear RNA and GAPDH as controls, respectively. All primers were synthesized by Takara Biotechnology Co. Ltd, and the primer sequences are shown in Table 3 .
In situ hybridization assay
In situ hybridization (FISH) was performed using a 5' DIG-labeled LNA probe (Exiqon, Co., Ltd., Vedbaek, Denmark) for miR-125b (sequence shown in Table 4 ) and miRCURY LNA™ Detection Control Probes (Exiqon) on 5-μm-thick sections fixed in 4% paraformaldehyde and embedded in paraffin. Briefly, the slides were deparaffinized with xylene and rehydrated in a graded ethanol series (2×100%, 95% 75%, 60%, and 50%). After washing with PBS, the slides were digested with 10 μg/mL proteinase K (Invitrogen) for 5 min at 37°C, rinsed in 0.2% glycine/PBS (5 min, 3 times), post-fixed in 4% paraformaldehyde for 10 min, and acetylated in acetic anhydride/triethanolamine at room temperature for 10 min before being washed in PBS. Then, the slides were prehybridized in hybridization buffer (50× Denhardts's solution; 60% formamide, 300 μg/ml transfer RNA, 20× saline sodium citrate (SSC) buffer and 1 M dithiothreitol (Invitrogen)) at 49.5°C for 30 min and hybridized with the probes (1:1000) at 49.5°C for 12 h. The slides were washed twice in 2× SSC at 49.5°C for 5 min, and the sections were blocked for 30 min at 37°C using 2% bovine serum albumin (BSA) (Sigma-Aldrich, Darmstadt, Germany). Subsequently, the anti-digoxigenin antibody (Roche Diagnostics, Basel, Switzerland) was added at a dilution of 1:400 and incubated at 37°C for 2 h. After being washed 3 times with PBS, the slides were incubated with tyramide signal amplification buffer (TSA, 1:50; Focofish, Inc, Guangzhou, China) at room temperature for 10 min in the dark and then washed 3 more times with PBS. Immunofluorescence was performed to determine SM-α-actin or SRF localization and expression using anti-SM-α-actin (1:1000, Abcam, Cambridge, UK) and anti-SRF (1:800, Cell Signaling Technology, Boston, MA, USA ) at 37°C for another 2 h. Finally, the slides were covered with a cover slip, photographed and analyzed using ImagePro Plus 6.0 (Media Cybernetics Inc., Rockville, MD, USA). The in situ hybridization probe sequences are shown in Table 4 .
Immunohistochemistry (IHC)/Immunofluorescence (IF)
Immunohistochemistry and immunofluorescence were performed on 5-μm-thick 4% paraformaldehyde-fixed, paraffin-embedded sections. The sections were heated at 60°C for 2 h, washed 2 times in xylene for 15 min and hydrated in an ethanol series (100%, 95% 75%, 60%, and 50%) for 5 min each. Then, the sections were washed with PBS 2 times, and heat-mediated antigen retrieval was performed Table 3 . Sequences of the PCR primers 
Western blot analysis
VSMCs (1×10 4 cells per well) were seeded in 6-well plates 24 h before transfection. After RNA interference was performed, the cells were cultured for an additional 72 h using normal medium. The cells were washed 3 times with PBS and lysed in RIPA lysis buffer (CST) supplemented with protease inhibitors (Roche Diagnostics). Total protein concentrations were determined using a NanoDrop 2000 microvolume spectrophotometer (Thermo Scientific). Total protein lysates were separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to polyvinylidene fluoride (PVDF) membranes (Millipore, Billerica, MA, USA). The membranes were blocked with 5% non-fat dry milk in TBS buffer at 37°C for 2 h and then incubated with the anti-human SRF (CST, 1:1000 dilution) and β-tubulin (CST, 1:1000) primary antibodies overnight at 4°C. The membranes were incubated with a secondary rabbit antibody at 37°C for 2 h. Relative protein expression levels were normalized to those of β-tubulin. The signals were detected using Luminol Reagent (Thermo Scientific) and imaged with a GE ImageQuant LAS 4000 phosphorimager (GE Healthcare Life Sciences, Fairfield, IA, USA) with ImageJ software (https:// imagej.nih.gov/ij/).
Cell proliferation
VSMCs (2×10 3 cells per well) were seeded in 96-well plates in triplicate 12 h before transfection. After RNA interference was performed, the cells were cultured for 24 h in normal medium and 24 h in serumfree DMEM. In addition to the control group, 20 ng/ml PDGF-BB was added to each well for 24 h. For the cell counting kit-8 (CCK-8) assay, 10 μl of CCK-8 solution (Dojindo, Tokyo, Japan) was added to each well for 1 h, and the absorbance values were then measured at 450 nm using a spectrophotometer. For the EdU assay, cells were incubated with 50 μM EdU (Ribobio) for 2 h and then fixed with 4% paraformaldehyde for 15 min. The cells were subsequently treated with 100 μl of Apollo reaction cocktail at room temperature for 30 min, followed by 50 μl of 1% Hoechst 33342 (Ribobio) at room temperature for 30 min for nuclei staining. Finally, an inverted fluorescence microscope (Axio Observer Z1, ZEISS, Oberkochen, Germany) was used for visualization. Ten random microscopic fields in each well were photographed and imaged, and the number of Apollo-positive nuclei was divided by the total number of nuclei stained with Hoechst 33342. Fluorescence images were analyzed using ImagePro ® Plus software 6.0 (Media Cybernetics).
Cell migration
Transwell and wound closure assays were used to assess cell migration. VSMCs were seeded in 6-well plates in triplicate 24 h before transfection. After RNA interference was performed, the cells were cultured for 24 h in normal medium and 24 h in serum-free DMEM. For the transwell assay, VSMCs were resuspended in serum-free DMEM (5×10 5 cells/ml) after digestion, and 200 µl of the mixture was added to the upper chamber of a Transwell insert (BD Falcon, Franklin Lakes, NJ, USA) in a 24-well plate. Next, 500 µl of serumfree DMEM with or without 10 ng/ml PDGF-BB was added to the lower chamber as the control. After 12 hours of incubation, cells migrated to the lower face of the chamber membrane, and cells remaining on the upper face of the membrane were removed by a cotton swab. Cells adhered to the lower face were fixed with 4% paraformaldehyde and subsequently stained with 0.1% crystal violet. After being washed three times with PBS, migrated VSMCs were imaged and counted using an inverted microscope (Axio Observer Z1, ZEISS, 20× magnification). For the wound closure assay, wounds in each well were scratched using a sterilized 200-μl disposable pipette tip, and the assay was performed in triplicate. The medium was replaced with serumfree DMEM supplemented with 10 ng/ml PDGF-BB in addition to the control group. Scratch wounds were immediately visualized using an inverted microscope (Axio Observer Z1, ZEISS). The cells were cultured
h and then visualized again at the previous position. The widths of the scratch wounds were measured using ImagePro ® Plus software 6.0 (Media Cybernetics).
Cell apoptosis
Flow cytometry analysis was used to evaluate cell apoptosis. VSMCs (1×10 5 cells per dish) were seeded in culture dishes 24 h before oligo transfection, and normal culture medium was replaced with serum-free DMEM for another 48 h. Cells were washed twice with PBS, digested with EDTA-free trypsin, harvested, and washed three more times with PBS. The cells were double-stained with FITC-conjugated V and propidium iodide (PI) from the detection kit (Dojindo) according to the manufacturer's instructions. The percentages of viable cells (annexin V-and PI-negative), apoptotic cells (annexin V-positive and PI-negative) and necrotic cells (annexin V-and PI-positive) were detected using an EPICS XL-MCL TM flow cytometry system (Beckman Coulter, Fullerton, CA, USA). The results were analyzed using Kaluza 1.2 software (Beckman Coulter).
3'-untranslated region (3'-UTR) luciferase assay
Using TargetScan 7.1 (http:// www.targetscan.org/), SRF was selected as a potential miR-125b target based on the complementarity of its mRNA 3'-UTR to miR-125b. SRF mRNA 3'-UTR miR-125b binding sites were amplified by PCR and cloned into the pLUC luciferase reporter vector (Kangbio, Guangzhou, China) to construct the fluorescent reporter system. pLUC vectors containing the SRF mRNA 3'-UTR with miR-125b-mutated binding site 1 (Mut1), miR-125b-mutated binding site 2 (Mut2), or miR-125b-mutated binding sites 1 and 2 (Mut1&2) were also generated. HEK293T cells were cultured in triplicate to 70% confluency in 96-well plates and co-transfected with the luciferase reporter vectors (either the wild-type or one of the three mutant SRF 3'-UTRs) and the miR-125b mimics or control oligo (Ribobio) (60 nmol/l) using FuGENE ® HD (Roche) according to the manufacturer's instructions. After 48 h, the cells were lysed, and luciferase activity was measured using the Dual-Glo™ Luciferase Assay kit (Promega, Madison, WI, USA) according to the manufacturer's instructions. Sequences of the 3'-UTR primers used for the luciferase assay are shown in Table 5 and Table 6 .
Lentiviral transduction
According to the manufacturer's instructions, HEK293 cells were re-cotransfected with 2.5 μg of the Lenti-Pac HIV plasmid (GeneCopoeia) and SRF cDNA (GeneCopoeia) to produce lentiviral particles. The particles were collected 48 h later, and serum-free medium containing 20 μg/mL polybrene (Sigma) was mixed with the filtrate (containing virus), incubated overnight with the cultured cells, and then replaced with growth medium for an additional 24 h. The cells were selected using 10 μg/mL puromycin (Sigma) for 2 days according to the manufacturer's instructions. The lentiviral particles were collected and stored at -80°C.
Rat carotid artery balloon injury model
The carotid artery balloon injury and lentivirus-mediated gene transfer were performed in SPF male Sprague Dawley rats (Silaike Jingda, Hunan, China) (250 to 300 g) as described previously [24] . Pentobarbital sodium (40 mg/kg) was used to narcotize the rats. The drugs were added until their pedal pinch reflexes were completely inhibited and they had no response to a needle stimulus. Anaesthetized rats were placed on a warming plate to maintain their body temperature at 37°C to minimize pain caused by the procedure. Using a dissecting microscope, the right common carotid artery was exposed through a midline cervical incision. A 2F Fogarty catheter (Edwards L i f e s c i e n c e s , Irvine, CA, USA) was inserted via an arteriotomy in the external carotid artery and pushed forward to the edge of the sternum, which was very near the omohyoid muscle edge. To induce the carotid artery wall injury, the balloon was dilated with saline and pulled backwards and forwards three times while continuously rotating the catheter from the edge of the sternum to the carotid bifurcation. Following the balloon injury, a solution containing miR-125b-LV (5×10 9 pfu/mL) and NC-LV (5×10 9 pfu/mL) was infused into the provisionally closed segment of the right common carotid artery by an artery clamp and held for 40 min. The right external carotid artery was then ligated with a 6-0 silk suture, and the artery clamp was relieved so that blood flow to the right common carotid artery was recanalized. The rats were sacrificed using pentobarbital sodium (150 mg/kg) 2 weeks later for analysis of the carotid artery balloon injury model. All protocols were authorized by the Institutional Animal Care and Use Committee of the First Affiliated Hospital of Sun Yat-sen University and were in accordance with the Guide for the Care and Use of Laboratory Animals (https://doi.org/10.1093/ilar/ilw049).
Statistical analyses
Statistical analyses were conducted with Student's t-tests for average (mean) comparisons or one-way ANOVA for multiple comparisons to identify significant differences. Relationships between variables were determined by the Pearson correlation coefficient. P-values<0.05 were considered significant. All data were processed using GraphPad Prism 5.0 and SPSS software (version 17.0).
Results

miR-125b expression was decreased in ASO arteries and PDGF-BB-stimulated VSMCs
Our previous study revealed miR125b expression to be significantly downregulated in ASO arteries compared with that in normal arteries. In the present study, we confirmed that miR-125b expression was significantly down-regulated by ~70% in ASO arteries compared with that in normal arteries using a qRT-PCR assay (Fig. 1A) . To determine the distribution of miR-125b in the artery wall, three ASO arterial layers were dissected, and miR125b expression was detected using qRT-PCR. As shown in Fig. 1B, miR-125b was expressed primarily in the artery media, which was mainly composed of VSMCs, rather than the intima and adventitia. To further assess the cellular distribution of miR-125b in the artery wall, we performed co-IF with the smooth muscle marker SM-α-actin. miR-125b (red) co-localized with SM-α-actin (green) in the artery media and was remarkably down-regulated in ASO arteries (Fig. 1C) . In addition, when VSMCs were stimulated with PDGF-BB (10 ng/ml, 0~48 h), miR-125b expression was down-regulated (Fig. 1D) . These findings indicate that miR-125b is expressed mainly in VSMCs and suggest that miR-125b is down-regulated in ASO VSMCs and PDGF-BB-stimulated VSMCs cultured in vitro. 
miR-125b inhibited VSMC proliferation and migration but promoted VSMC apoptosis
Excessive VSMC proliferation and migration are key cellular events in the process of arteriosclerosis [25] . To explore the cellular effects of abnormal miR-125b expression in ASO, we introduced miR-125b mimics into cultured VSMCs. Fig. 2A-C shows that the proliferation of PDGF-BB-stimulated VSMCs was significantly inhibited by the miR-125b mimics, as determined by the CCK-8 and EdU assays, and miR-125b significantly decreased the PDGF-BB-induced migration of VSMCs (Fig. 2D-G) . In addition, the annexin V/PI dual staining assay showed that miR-125b markedly increased the number of apoptotic VSMCs (Fig. 2H-I) . These results revealed that miR-125b might suppress VSMC proliferation and migration but promotes VSMC apoptosis in vitro.
SRF is a direct target of miR-125b
As predicted by TargetScan 7.1, SRF was selected as a potential miR-125b target based on its mRNA 3'-UTR complementarity to miR-125b. miR-125b was predicted to target two potential regions of the SRF mRNA 3'-UTR (bp 470-476 and bp 2055-2061) (Fig. 3A) .
Analyzing human ASO and normal artery samples by Western blot and IHC showed that the SRF protein level in ASO arteries was significantly higher than that in normal arteries (Fig. 4A-D) . In contrast, FISH analysis showed that the miR-125b level in ASO arteries was significantly lower than that in normal arteries (Fig. 1B-C) . These results indicated a 
negative correlation between SRF and miR-125b expression in vivo. Moreover, in cultured VSMCs, miR-125b mimics significantly decreased SRF protein expression, while the miR125b inhibitor moderately increased SRF protein expression ( Fig. 3B and C) . In addition, miR-125b slightly down-regulated the SRF mRNA level (Fig. 3D ). These findings suggest that The SRF mRNA levels were minimally d o w n -r e g u l a t e d by miR-125b mimics but slightly upregulated by the miR-125b inhibitor (60 nmol/L), as assessed by qRT-PCR. *p<0.05 compared with the vehicle group. (E) Co-transfection of miR-125b mimics with the wild-type SRF 3'-UTR (WT) or either of the two SRF 3'-UTR mutants in HEK293T cells led to a marked decrease in luciferase activity, whereas co-transfection of the miR-125b mimics with the two completely mutated SRF 3'-UTRs had no effect on luciferase activity. *p<0.05, **p<0.01 compared with the WT+NC group. (F) Overexpression of SRF in VSMCs was achieved using a lentivirus vector (LV-SRF), and LV-SRF expression could not be effectively suppressed by the miR-125b mimics, as determined by Western blot analysis. *p<0.05 compared with the LV-control group. (G-I) The proliferative capacity of cultured VSMCs was partly recovered by the administration of SRF lentivirus, as determined by CCK-8 and EdU assays. *p<0.05, **p<0.01 compared with the vehicle-treated miR-125b mimic group. (J-M) The effect of miR-125b suppression on the migration of cultured VSMCs was partly attenuated by the administration of SRF lentivirus, as determined by transwell and wound closure assays. **p<0.01 compared with the vehicle-treated miR-125b mimic group. (N-O) The SRF lentivirus partly alleviated the promotional effects of miR-125b mimics on the apoptosis of cultured VSMCs, as shown by the annexin V/PI dual staining assay. *p<0.05, **p<0.01 compared with the vehicletreated miR-125b mimic group. To investigate whether miR-125b directly binds the SRF mRNA 3'-UTR and consequently regulates its expression, two putative miR-125b binding sites in the SRF mRNA 3'-UTR region were constructed in a dual-luciferase reporter vector. In the presence of the wild-type SRF mRNA 3'-UTR and either of the two SRF mRNA 3'-UTR mutants, miR-125b significantly decreased the relative luciferase activity. When the two miR-125b seed sequences in the SRF mRNA 3'-UTR were totally mutated, the inhibitory effect of miR-125b on the relative luciferase activity was abrogated. The suppressive degree of the mut2 3'-UTR position was more remarkable than that of the mut1 3'-UTR. (Fig. 3E) . We hypothesized that the 2nd 3'-UTR position has a stronger ability to bind miR-125b mimics. Together, these results confirmed that SRF is a direct target of miR-125b.
Additionally, to determine whether SRF is involved in cellular effects induced by miR-125b, we overexpressed SRF in VSMCs via an SRF lentiviral vector (LV-SRF) (Fig.  3F) . The core LV-SRF sequence contained the SRF coding sequence but not its 3'-UTR, thus eliminating the miR-125b binding sites, and the miR-125b mimics could not inhibit SRF expression induced by LV-SRF (Fig.  3F ). As shown in Fig. 3G -M, overexpressing SRF by LV-SRF significantly attenuated the antiproliferative and antimigratory effects of miR-125b mimics. The annexin V/PI dual staining assay demonstrated that overexpressed SRF markedly weakened the apoptosis-promoting effect of miR-125b in VSMCs (Fig. 3N-O) . Taken together, these data indicate that SRF is a direct target of miR-125b and is involved in miR-125b-induced cellular effects.
Exogenous miR-125b expression regulated SRF expression and suppressed vascular neointimal formation in balloon-injured rat carotid arteries
To explore the effects of miR-125b on VSMC proliferation and neointimal formation in vivo, we used a rat carotid balloon injury model and induced an miR-125b lentiviral vector (LV-miR-125b) to regulate miR-125b expression in the vascular wall. After successful transfection, LV-miR-125b overexpressed miR-125b. The LVs were delivered to the vascular wall after the balloon injury as described. In balloon-injured arteries, neointima formation was found, and the neointima thickness was decreased, as determined by hematoxylin and eosin (H&E) staining and calculation of the neointimal area (Fig. 5A-B) .
After the balloon injury, miR-125b expression in the vascular wall was significantly decreased compared with that in uninjured vascular samples, and LV-miR-125b reoverexpressed miR-125b in the injured vascular walls, as detected by qRT-PCR and FISH (Fig. 5C, 5F-H) . Furthermore, LV-miR-125b significantly suppressed neointimal formation in rat carotid arteries after the balloon injury ( Fig. 5G-H ). As shown in Fig. 5F -H, the balloon injury significantly increased SRF expression. However, a co-FISH-IF assay demonstrated that after inducing LV-miR-125b, SRF expression decreased as miR-125b expression increased. These results also indicated a negative correlation between SRF and miR-125b expression in vivo. Furthermore, investigation of the proliferation marker Ki67 revealed that LV-miR125b significantly inhibited VSMC proliferation in vivo, as determined by Western blot and IHC (Fig. 5D-E) . All of the present findings revealed that exogenous miR-125b expression suppressed neointimal formation by targeting SRF.
Discussion
In previous research, we profiled microRNA expression characteristics in normal and ASO human arteries using a microRNA qRT-PCR array [12] , revealing miR-125b expression to be significantly down-regulated in the arteries of ASO patients. In this study, we revealed the distribution of miR-125b in human ASO arteries and found that miR-125b exhibited tissue tropism, as it was mainly localized in VSMCs of the artery wall. These characteristics indicate that miR-125b may affect the function of VSMCs in ASO.
The two miR-125b binding sites in the 3'-UTR of SRF mRNA and the negative correlation between miR-125b and SRF in ASO and normal vascular arteries in vivo suggest that SRF may be a miR-125b target. To explore this possibility, we first used a luciferase reporter assay to validate that miR-125b directly binds SRF 3'-UTR regions to regulate SRF expression. Then, 
Cellular Physiology and Biochemistry
Cellular Physiology and Biochemistry we confirmed that miR-125b could not inhibit SRF expression induced by LV-SRF, which lacks miR-125b binding sites. Overexpressing SRF by LV-SRF significantly attenuated the antiproliferative and antimigratory effects of miR-125b, suggesting that SRF is a functional downstream target of miR-125b and is involved in the miR-125b-mediated modulation of VSMC function. SRF is a highly conserved and widely expressed single-copy transcription factor that plays extensive role in circulatory system such as cardiac function and hypertension [26, 27] . SRF theoretically binds up to 1, 216 permutations of a 10-base pair cis element known as the CArG box [28] . Furthermore, SRF is a transcription factor that binds CArG box elements in promoter regions of target genes that are associated with VSMC differentiation [29] [30] [31] . SRF regulates two distinct VSMC gene programs, SMC differentiation genes (SM-α-actin, SM-MHC), which are linked to muscle differentiation, and growth-related immediate early genes (IEG, Fos/c-fos), which promote cellular growth [29] . SRF must toggle between the VSMC differentiation and growth programs depending on its co-activator and local environmental cues. Myocardin is a muscle-restricted SRF co-activator that forms a ternary complex with SRF to activate VSMC differentiation gene expression [29] . Myocardin greatly increases the association of SRF with SM-α-actin and SM-MHC CArG boxes, but not c-fos CArG boxes, to promote transcription [32] .
Ligands and receptors of PDGF-BB are up-regulated in both human atherosclerotic plaques [33, 34] and in rat and baboon neointimal tissues induced by injury or vascular grafting [35, 36] , and PDGF-BB is highly released after vessel injuries, such as ballooninduced femoral artery injuries [37] .
PDGF-BB is a well-characterized signaling molecule that induces VSMC phenotypic switching, including profound transcriptional repression of VSMC gene expression, in cultured VSMCs. PDGF-BB treatment decreased myocardin expression and induced decreased SRF binding to SM-α-actin and SM-MHC CArG boxes [32] .
PDGF-BB is well known as an atherosclerosis promotional factor [38] , and it induces the phosphorylation of Elk-1 through MEK1/2 and competes for SRF binding to CArG elements in the promoters of VSMC marker genes [39] . In addition, the phosphorylation of Elk-1 increases SRF binding to the c-fos promoter and transcriptional activation in response to growth factors [40, 41] . A previous study demonstrated that PTEN might interact with the N-terminal domain of SRF, and PTEN-SRF complex interactions promoted the binding of SRF to essential promoter elements in SMC differentiation genes [42] . PDGF-BB represses SMC differentiation gene transcription at least in part by regulating SRF binding to the CArG boxes of SMC differentiation genes [32] . PDGF-BB stimulation reduced the expression of PTEN, SRF and SM-α-actin, which was associated with a loss of PTEN binding and reduced SRF binding to CArG boxes on SMC differentiation gene promoters. However, this phenomenon increased SRF binding to c-Fos CArG boxes, further promoting the proliferation and migration abilities of VSMCs [42] .
SRF has also been demonstrated to be essential for maintaining the homeostasis of VMSC actin cytoskeleton, which is associated with cell migration [43] . Numerous actin cytoskeleton genes are direct targets of SRF, and activated genes encoding the cytoskeletal apparatus indirectly stimulate SRF activity. The positive feedback mechanism of the SRF/ actin cytoskeleton loop is vital for cytoskeletal homeostasis and cell migration ability [31] .
Taken together, PDGF-BB together with SRF might promote the migration of VSMCs from the vessel media to the intima, thus promoting excessive proliferation under certain circumstances, and SRF acts as a key factor in this scenario. However, miR-125b degraded SRF mRNA and negatively regulated SRF expression at the post-transcriptional level to regulate this important biological process.
In the absence of the SRF 3'-UTR, SRF up-regulation via the administration of SRF lentivirus markedly promoted the proliferation and migration abilities of VSMCs even when miR-125b mimics were added simultaneously. In the IHC assay, increased levels of SRF were accompanied by neointimal formation, indicating that SRF has proproliferation and promigration effects on VSMCs under this condition.
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In the carotid artery balloon injury model, overexpressing miR-125b in the rat arteries led to the down-regulation of SRF and the inhibition of VSMC proliferation and neointimal formation. These results further confirmed SRF as a miR-125b target in vivo and indicated that exogenous miR-125b expression may be used to inhibit the progression of ASO and vascular restenosis.
Conclusion
In summary, the present study revealed that down-regulated miR-125b expression is a novel regulator of vascular neointimal growth and function due to the regulation of VSMC proliferation and migration via directly targeting SRF, and exogenous miR-125b may inhibit VSMC proliferation and migration. These findings offer new insights that may be useful in the treatment of arteriosclerosis, vascular restenosis, and other proliferative vascular diseases.
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